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Introduction
Prostate cancer is the most common form of cancer in
men in Western countries and the second leading cause of
cancer related mortality after lung cancer. The disease
exhibits a wide spectrum of behaviour: it can be cured
if discovered early but it is a slow-growing malignancy
that may lead to an agonizing death if left untreated.
Alternatively, many people may harbour prostate cancer
without any signs or symptoms, with the tumour only to
be discovered at autopsy. However, diagnosis often is
complicated by co-morbid conditions, such as prostatitis
or benign prostatic hypertrophy that are part of the
normal aging process. Despite the theoretical benefits of
early screening and detection, the impact on survival
remains controversial and the dilemma lies in the long
natural history of the disease. Many prostate cancers can
be so indolent that a strategy of watchful waiting is
a treatment option: hence early discovery of prostate
cancer may not affect treatment outcome although it gives
rise to much anxiety for patients and family. It is also
remarked that currently many countries are undertaking
opportunistic screening in that family practitioners order
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The introduction and increasing use of the PSA test in the late 80's to early 90's has revolutionized the diagnosis and follow-
up of the disease, although the benefits and limitations of the test remain incompletely understood. Only a small proportion
of cancers become clinically evident: more men die with the disease rather than of the disease. Screening will thus identify some
men with cancer who will not benefit from treatment and it is unclear whether screening would be followed by a reduction in
morbidity and mortality. When prostate cancer screening is performed, it should consist of both PSA measurement and
digital rectal exam, as these tests are complementary in the early detection of prostate cancer. It is not yet known whether
prostate cancer screening improves survival, although this question will hopefully be answered by ongoing clinical trials. While
a global recommendation in favour of the practice is not currently warranted, there is considerable patient and physician
demand for prostate cancer screening. It therefore appears reasonable to provide screening on request to men aged 50 years and
older with at least a 10 year life expectancy, provided they are aware of the controversy surrounding the practice and of the
possible implications of a positive or a negative result.
Badania przesiewowe w kierunku raka prostaty – uwagi praktyczne
Wprowadzone na prze∏omie lat osiemdziesiàtych i dziewi´çdziesiàtych badanie PSA zrewolucjonizowa∏o leczenie raka
prostaty – tak w zakresie diagnostyki, jak i rokowania, aczkolwiek zarówno mo˝liwoÊci i ograniczenia tego badania nie sà
jeszcze zapewne w pe∏ni poznane. Tylko niewielki odsetek przypadków raka prostaty ujawnia si´ klinicznie – wi´cej chorych
umiera z rakiem prostaty ni˝ na raka prostaty. Wprowadzenie badaƒ przesiewowych umo˝liwi wykrycie raka prostaty równie˝
u tych chorych, którzy potencjalnie nie odniosà ˝adnej korzyÊci z leczenia, a zatem nie jest jasne, czy badania przesiewowe
spowodujà zmniejszenie ÊmiertelnoÊci z powodu tego w∏aÊnie nowotworu. Badania przesiewowe w kierunku raka prostaty
powinny obejmowaç badanie poziomu PSA i badanie per rectum, jako typowe dla rozopoznania wczesnego raka prostaty. Nie
wiadomo, czy badania przesiewowe poprawià prze˝ycie w raku prostaty, ale trwajàce obecnie badania kliniczne powinny daç
odpowiedê na to pytanie. Jak dotychczas badania przesiewowe w tym kierunku nie sà powszechne, ale istnieje du˝e
zapotrzebowanie na ich wprowadzenie, wyra˝ane zarówno przez pacjentów, jak i przez lekarzy. Wydaje si´ byç wskazane obj´cie
badaniami przesiewowymi m´˝czyzn powy˝ej 50 roku ˝ycia, którzy wyra˝à ch´ç poddania si´ badaniu i których spodziewane
prze˝ycie przekracza 10 lat pod warunkiem, ˝e zostali poinformowani o kontrowersjach zwiàzanych z badaniem i o mo˝liwych
implikacjach, zarówno pozytywnych, jak i negatywnych wyników.
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a prostate specific antigen (PSA) blood test only for the
occasional concerned patients.
Requirements for a screening programme with
special reference to prostate cancer
The requirements for a screening programme can be
defined under five main categories, Table I, of disease
requirement, test requirement, availability and com-
pliance, cost-effectiveness and avoidance of bias.
Should screening be undertaken?
Proponents of screening emphasize that early detection
can lead to discovery of organ confined disease and the
potential for cure. Opponents point to the lack of credible
evidence that screening is associated with a decrease
in mortality. In addition, population based screening,
with subsequent diagnosis and treatment in many
men, can be associated with considerable treatment
morbidity and mortality for a disease that is often not
fatal. Therefore the risks of over-diagnosis (knowledge
of having a cancer) and of overtreatment (impotence,
incontinence, perioperative death) must be emphasised.
Two studies by the European Organization for
Research & Treatment of Cancer (EORTC) [1] and by
the Radiation Therapy Oncology Group (RTOG) [2],
both for stage T3 disease, have shown that long-term
androgen blockade prolongs life in patients receiving the
androgen blockade in addition to radiotherapy, when
compared to radiotherapy alone. For the EORTC study
long-term was defined as three years, and for the RTOG
study long-term was defined as indefinite.
In the United Kingdom Medical Research Council
study, androgen blockade at diagnosis of locally advanced
or asymptomatic patients decreased cancer-specific death
compared to delayed treatment [3]. A 69% decrease in
prostate cancer death was observed in the Quebec ran-
domised prostate cancer screening study [4]. However
there is a dispute if the decrease in mortality is related
to recent advances in cancer treatment or early diagnosis
of the prostate cancer. Population-based studies in
Sweden and Denmark have shown that 62% and
63%, respectively, of patients diagnosed with localised
prostate cancer will die from the disease if not treated
immediately [5]. Decreases in prostate cancer death rate
of 6.3-23% have been found between 1991 and 1997 in
the USA and Canada, respectively. The treatment of
localised disease has been shown in all the available ran-
domised studies to cause a marked decrease in prostate
cancer death [5].
As a rough estimate, the risk of a 50-year-old man
with a 25-year life expectancy of having microscopic can-
cer is 42%, of having clinically evident cancer is 9.5%,
and of dying of prostate cancer is 2.9% [6]. Only a small
proportion of cancers become clinically evident: more
men die with the disease rather than of the disease.
Screening will thus identify some men with cancer who
Table I. Requirements for a screening programme
Disease requirement
Detectable at the pre-clinical stage: Yes
Survival for early stage disease is better than late stage disease: Yes
Current treatment more efficacious at an earlier stage: Yes
Treatment agreed upon for all cases, especially those cases that are borderline: No
Prevalent: Yes
Major cause of death: Yes
Negative effect outweighed by the benefit: Questionable, because early treatment of detected cancers may give rise to overtreatment and
unnecessary morbidity
Test requirement
Safe: Yes
Cheap: Yes
Sensitive: Yes
Specific: Yes, to a certain extent
Tolerable: Yes
Availability and compliance
Sufficient diagnostic and treatment facilities of adequate quality to manage the anticipated workload: Depends on individual countries
Physicians and other providers will comply with the recommended testing, treatment and follow-up protocol: Yes
Patients will comply with the testing, treatment and follow-up protocol: Depends on many factors, e.g. well-informed public, physician enthusiasm
Cost-effectiveness
How does the cost-effectiveness of the program compare with those of other health-care programs that are currently competing for the existing
resources? More research needed
Avoidance of bias
Lead time bias: The cancer will be detected much more early before clinical manifestation
Length time bias: Due to the slow clinical course of the prostate cancer
Volunteer bias: Those with genito-urinary symptoms or well-informed are more likely to attend screening
Overdiagnosis bias: Because detected cancers may not be clinically significant
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will not benefit from treatment and it is unclear whether
screening would be followed by a reduction in morbidity
and mortality.
Which populations should be screened?
About 99% of prostate cancers occur in men over 50
years of age. Currently the application of screening to
the general male population is still controversial even
though some individuals are at high risk for prostate
cancer. These high risk populations are: Africans, those
with family history of prostate cancer [7, 8], those
potentially linked to the hereditary prostate cancer 1
(HPC1) locus on chromosome 1q24-25 [9] and male
carriers of BRCA1/2 mutations [10]. There is a 2-fold
and 4-5 fold increased risk in men with one, or with 2 or
more affected first-degree relatives respectively. There
are no established modifiable risk factors [11].
Which populations are missed in screening
programmes?
Which populations are missed in screening programmes?
Compared with those who attend for screening, those
who refuse screening tend to be significantly older, less
often married and have a lower level of education. They
also have less knowledge about prostate cancer and a less
positive attitude towards screening; they have worse
general health but fewer urological complaints (American
Urological Association symptom score, AUA7 median 2
versus 4, P<0.001), as found from the European
randomised study of screening for prostate cancer
(ERSPC) in 1995-1996 [12]. Reasons for refusal were
absence of urological complaints, 57%, and anticipated
pain or discomfort, 18%. The main reported motives for
attending screening were personal benefit, 82%,
contribution to science, 49%, and presence of urological
complaints, 25%.
What are the best screening tests?
In the past, digital rectal examination (DRE) and acid
phosphatase were used but nowadays there are more
useful parameters for screening such as PSA which
is a very important test. In men with PSA <1.0 ng/ml,
1.0-1.9 ng/ml, 2.0-2.9 ng/ml and 3.0-3.9 ng/ml, the
detection rate of prostate cancer was respectively 4%,
15%, 27% and 29%. Also, there were no significant racial
differences in the PSA adjusted cancer detection rate or
in the Gleason score of detected disease [13].
C u t - o f f  v a l u e s ,  s e n s i t i v i t y  &  s p e c i f i c i t y
The ratio of free prostate specific antigen (FPSA) to total
prostate specific antigen (TPSA) in men is generally
chosen for screening purposes to have a cut-off value of
0.15 in order to avoid unnecessary biopsies in men with
serum TPSA concentration of 4-10 ng/ml. The predictive
value of TPSA in this range was 21%, but the predictive
value of the FPSA/TPSA ratio of 0.15 was better, at 78%,
maintaining at least 90% sensitivity [14].
In patients with TPSA values in the range 4-10 ng/ml
the cut-off value of the FPSA/TPSA ratio of 0.15 can be
used to eliminate unnecessary biopsies with minimal loss
of cancer patient detection. Patients with TPSA values
of less than 4 ng/ml were biopsied if they had positive
DRE and/or a FPSA/TPSA ratio lower than 0.15. Basso's
finding also suggests that the FPSA/TPSA ratio is an
excellent index [15]. However, on the contrary, a study
using stored serum samples concluded that there was no
material advantage in adding free to total PSA in prostate
cancer screening trials [16].
As well as the measurement of the percentage FPSA,
various other methods have been proposed to increase
the specificity of PSA measurement as a screening test.
These include age-specific PSA reference ranges and PSA
density (PSAD) derived from PSA/volume of the prostate
gland [17]. Age-specific PSA cut-offs miss 20-60% of
cancers in men older than 60 years of age [18].
Percentage FPSA and PSAD performed equally well
for detection of prostate cancer, both with a 95%
sensitivity, if cut-offs of 25% FPSA or 0.078 PSAD were
used. The commonly used PSAD cut-off of 0.15 detected
only 59% of cancers. Percentage FPSA and PSAD also
produced similar results for prediction of the post-radical
prostatectomy pathological stage. Patients with cancer
with high percentage FPSA values of >15% or lower
PSAD values of ≤0.15, tended to have less aggressive
disease. The results demonstrate that the sensitivity of
cancer screening detection is significantly higher with
percentage FPSA than with age-specific PSA reference
ranges. Percentage FPSA and PSAD provide comparable
results, suggesting that percentage FPSA may be used
in place of PSAD for biopsy decisions and in algorithms
for prediction of less aggressive tumours since the
determination of percentage FPSA does not require
ultrasound [18].
The complex between PSA and alpha1-protease
inhibitor in serum can be used to reduce further the
number of false-positive PSA screen results independent
of the total and free PSA. In a Finnish study of 304
consecutive PSA screen positive subjects, including 78
with and 226 without prostate cancer, and serum PSA of
4-10 ng/ml or >10 ng/ml, the proportion of serum PSA-
alpha1-protease inhibitor of total PSA was lower in cancer
cases than in controls: (0.9% versus 1.6%, P<0.001).
Serum PSA-alpha1-protease inhibitor improves the
specificity of total and free PSA in a screening population
with total PSA 4-10 ng/ml [19].
PSA density of the transition zone (PSATZD),
derived from the PSA/volume of the transition zone, has
been shown to be the most useful and valid method for
the differentiation between prostate carcinoma and
benign prostatic enlargement in the overall patient
population and in patients with intermediate PSA levels
[20]. Between October 1997 and August 1999, systematic
sextant biopsies were performed on 281 patients,
including 147 with PSA levels between 4.1 ng/ml and
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10.0 ng/ml. The clinical values of PSA, the FPSA to TPSA
ratio, alpha-1-antichymotrypsin-PSA complex (PSA-
ACT), PSAD, and PSATZD for the detection of prostate
carcinoma were compared by using receiver operating
characteristic (ROC) curves and logistic regression
analyses. According to the ROC curve analysis, PSATZD
had the greatest area under the curve in the overall
patient population and in patients with intermediate PSA
levels. In patients with intermediate PSA levels, at
a sensitivity of 90%, PSATZD would have prevented
unnecessary biopsies in 68/117 patients who were without
prostate carcinoma, whereas PSA, FPSA/TPSA ratio, and
PSA-ACT would have prevented unnecessary biopsies in
25, 28, and 25 patients, respectively [20]. ROC curve
analysis for PSATZD showed that by using a PSATZD
>0.22 ng/ml/cc as a biopsy criterion, 24.4% of negative
biopsies could be avoided without missing the detection of
a single carcinoma [21].
An elevated PSA does not always mean adeno-
carcinoma of prostate, lymphoma can cause an elevated
PSA [22]. On the other hand, the torti-potential nature of
the basal or reserve cells normally present in the prostate
acini theoretically may develop into mixed tumours. In the
same gland, adenocarcinoma may develop in addition to
lymphoma.
False-positive elevation of PSA has been reported
due to disease processes outside the prostate gland with
the use of the polyclonal assay. Such false-positive test
results have been exceedingly rare with the use of the
monoclonal assay. A case of B-cell lymphoma of the
kidney had been reported to have a significant elevation
of serum PSA levels by the monoclonal assay in the
absence of either inflammatory or malignant prostate
disease. PSA returned to normal during lymphoma-
specific chemotherapy [23].
W h a t  i s  t h e  a p p r o p r i a t e  c u t - o f f  v a l u e  f o r
P SA  s c r e e n i n g ?
It has recently been suggested that the diagnostic
threshold for the PSA assay be lowered to enhance
prostate cancer detection. A 24.5% (37/51) incidence
of prostate cancer has been reported in men with PSA
between 2.5 ng/ml and 4.0 ng/ml [24]. The age-adjusted
upper PSA reference values for the three age categories
studied of 55-59 years, 60-64 years and 65-70 years, were
5.2 ng/ml, 5.8 ng/ml, and 6.7 ng/ml, respectively [25].
In a screening setting the widely accepted 25-30%
positive predictive value (PPV) for PSA >4.0 ng/ml may
only apply to white males. A higher PPV of 36-60% is
more accurate for black males [26]. Due to the observed
higher age-specific serum PSA values in African-
American males without prostate cancer compared to
white males, this has led some to recommend race-specific
PSA reference ranges for the early detection of prostate
cancer. However Cooney has showed that among 432
African-Americans, the 95th percentile PSA values were
estimated to range from 2.36 ng/ml for men in the fifth
decade to 5.59 ng/ml for men in the eighth decade [27].
The 95th percentile values for age-specific PSA were
comparable to those observed in a similar study of white
males in Olmsted County, Minnesota. The median and
5th percentile values for FPSA/TPSA did not vary
significantly with age. Cooney concluded that the minor
differences in PSA reference ranges between African-
American and white males may not be of sufficient
magnitude to recommend the use of race-specific PSA
reference ranges for screening.
When should screening be performed?
PSA and DRE examination should be performed between
the age of 50 and 70 years when life expectancy exceeds
10 years. In cases of positive family history the screening
should start at the age of 40-45 years [9, 28, 29]. Annual
screening seems to be reasonable to avoid missing interval
cancers. However there are exceptions to this strategy:
the combination of PSA levels <3.0 ng/ml and
a percentage FPSA >18% defines a population at a very
low risk of cancer of the prostate both at the time of
screening and during the following five years. Men in this
group may be spared DRE, and longer screening intervals
may be considered [30].
Unfortunately due to increasing public awareness,
physician liability for delay of diagnosis may be difficult to
defend in the court. Hence more PSA tests are offered as
a routine in the US and Canada.
Is screening cost-effective?
To address cost-effectiveness, the Quebec prospective
randomized controlled trial on 46,193 men aged 45-80
years, which was completed in November 1988,
demonstrated for the first time that early diagnosis and
treatment permits a dramatic decrease in deaths from
prostate cancer [4]. But the result is still being disputed.
The other randomized trial, the ERSPC that was
performed in five European countries will not have results
available until the year 2007 [31]. Similarly the National
Cancer Institute prostate, lung, colorectal, ovarian cancer
screening (PLCO) trial, which is a 16-year randomised
control study that began in November 1993 cannot yet
report any results [32].
The cost of screening was estimated to be 501 French
Francs (FF) per person screened and 91,000 FF per
cancer detected, based on a theoretical screening protocol
and the epidemiological data available in France. The
mean cost of curative treatment was estimated to be
44,000 FF per cancer. The theoretical global cost of
screening and treatment was estimated to be between 4
billion FF and >10 billion FF [33].
Although men 50-70 years old will potentially benefit
the most from PSA screening, this benefit will not be
realised until they are in their seventh or eight decade
of life. Society must therefore decide if the years of life
saved in these men warrant the use of its limited health
care resources. This decision will be easier to make when
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more randomised, controlled trials are available to
quantify the costs and benefits of PSA screening.
What action to take following abnormal initial
results?
Treatment in older patients should be guided by health
status and personal preferences. For those likely to die of
causes unrelated to the cancer, should a biopsy be done?
What is the best biopsy technique? Although the
sextant biopsy technique has been widely used, concern
has arisen that this method may not include an adequate
sampling of the prostate, especially for large prostates. In
patients with a total prostate volume >45 cm3 and
transitional zone volume >22.5 cm3, a single set of sextant
biopsies may not be sufficient to rule out cancer. In these
patients, a repeat biopsy should be considered in the case
of a negative first biopsy [34].
Sometimes the biopsy may be reported as high-grade
prostatic intraepithelial neoplasia (PIN). What to do
about the presence of PIN is just as confusing and
controversial as it ever was. PIN is a considerable risk
factor for the presence of prostate cancer, with up to
73% of patients having cancer on rebiopsy. The World
Health Organisation Collaborative Project and Consensus
Conference on Public Health and Clinical Significance
of Premalignant Alterations in the Genitourinary Tract
[35] recommended the following. (1) Only patients
considered for curative treatment of prostate cancer
be further investigated for a PIN biopsy finding. (2)
A palpable nodule or tumour suspicious transrectal
ultrasonography (TRUS) finding, in conjunction with
a finding of high grade PIN on prostate biopsy, should
prompt rebiopsy. (3) An elevated PSA level or an
elevated PSA density should also warrant repeat biopsy,
as the most likely cause of PSA elevation is concomitant
prostate cancer. (4) The presence of high grade PIN on
biopsy without concomitant prostate cancer in patients
suitable for curative treatment, notwithstanding normal
DRE, TRUS or PSA, should prompt repeat biopsies, as
the association with prostate cancer is significant. (5) The
presence of PIN alone on biopsy does not warrant
treatment, as a substantial number of rebiopsies yield
only PIN.
Various approaches have been suggested for the
prevention and treatment of high grade PIN. One
approach may be to put patients on total androgen
blockade since high grade PIN is androgen-dependent.
Patients who are pretreated prior to surgery with
hormone deprivation have less PIN at time of radical
prostatectomy. As well, PIN is radio-sensitive, hence
radiotherapy may be an option. The only way to learn
about the natural history and treatment of this condition
is to conduct trials.
The next step after biopsy proof is to decide if
patient should be treated now or have watchful waiting.
A Gleason score of 5,6, or 7 predicts slow progression.
The doubling time of PSA should be checked on follow-
up. Counselling of patient and family is required to
alleviate anxiety for watchful waiting.
Screening in the United States of America
The prostate-specific antigen test was approved by the
U.S. Food and Drug Administration in 1986 to monitor
the disease status in patients with prostate cancer and,
in 1994, to aid in prostate cancer detection. However,
after 1986, the test was performed on many men who
had not been previously diagnosed with prostate cancer,
apparently resulting in the diagnosis of a substantial
number of early tumours. There is indirect evidence from
208,234 prostate carcinoma cases diagnosed between 1973
and 1993 in the population based Surveillance, Epidemio-
logy and End Results (SEER) program registries that
prostate carcinoma screening of men age >50 years
decreased the incidence of distant disease, which in turn
influenced the mortality rate [36]. The most updated
revised prostate cancer screening guidelines of the
American Cancer Society recommend that men be
informed of the risks associated with prostate cancer
screening, e.g., impotence from treatment [36].
Screening in Canada
Retrospective data from the Saskatchewan Cancer
Registry, one of the oldest provincial registries in Canada,
showed there is no survival difference of prostate cancer
patients before and during the PSA era [37]. However,
a prospective randomised controlled trial in Quebec on
46,193 men aged 45 to 80 years showed a survival benefit
for screening [4]. At first visit, screening included a DRE
and a measurement of serum PSA using 3.0 ng/ml as the
upper limit of normal. TRUS was performed only if PSA
and/or DRE was abnormal and biopsy was then
performed, only if PSA was above the predicted PSA
value. At follow-up visits, PSA alone was used as pre-
screening. 137 deaths due to prostate cancer occurred
during the period 1989-1996 in the 38,056 unscreened
men while only five deaths were observed among the
8,137 screened individuals. The prostate cancer death
rates during 1989-1996 were 48.7 and 15 per 100,000 man-
years in the unscreened and screened groups, respectively,
for a 3.25 odds ratio in favour of screening and early
treatment, P<0.01. It was concluded that if PSA screening
is started at the age of 50 years, or at 45 years in the
higher risk population; annual or biannual PSA alone is
highly efficient to identify the men who are at high risk of
having prostate cancer. Coupled with treatment of
localised disease, this approach demonstrates, for the
first time, that early diagnosis and treatment permits
a dramatic decrease in deaths from prostate cancer [4].
However its result has been disputed.
Due to the shortage of radiation technologists,
oncologists and diagnostic radiologists in Canada, the
impact of routine screening for prostate cancer will be
very great. It will drain a lot of resources from the
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universal Medicare system. Currently, PSA screening is
not done on a population basis.
Screening in the United Kingdom
In the United Kingdom, a 1997 national guidance
executive letter EL(97)12 stated that population screening
should not be provided by the National Health Service, or
be offered to the public until there is effective screening
technology for prostate cancer. However, it has recently
been reported in the press, The Sunday Times of 25 March
2001, that the UK Government has changed its position
and some limited form of screening will be introduced
sometime in the future.
Screening in the Netherlands
The evaluation of the screening procedures for prostate
cancer was a part of the protocol of the European
randomized study of screening for prostate cancer
(ERSPC) [38]. In June 1996, 8612 men, aged 55-74 years
were randomised and were screened within the ERSPC in
Rotterdam by a PSA level of ≥4.0 ng/ml or a positive
DRE or TRUS findings as the indication for biopsy:
430 men had prostate cancer. The protocol was
changed in February 1997 and another 7943 men were
screened according to the new protocol of a PSA level of
≥3.0 ng/ml. The resulting data were used to compare the
two protocols.
The detection rate, defined as the proportion of
cancer in those screened, was found to be very similar
with rates of 5.0 and 4.7 at PSA cut-offs of respectively
≥4.0 ng/ml and ≥3.0 ng/ml. There was a much larger
number of cases of prostate cancer per biopsy in the PSA
range of 3.0-3.9 ng/ml than were expected. Tumour
characteristics were studied on radical prostatectomy
specimens from the original protocol. Prostate cancer
detected with the new screening regimen had a similar
distribution of Gleason scores but a larger proportion of
organ-confined disease. Tumour volumes were smaller
in patients with PSA levels of less than 2.9 ng/ml; the
proportion of minimal disease in that group was
50% compared with 28% in the group with a PSA level
3.0-3.9 ng/ml. Changes were noted in the incidence and
treatment of prostate cancer over the period in which
new diagnostic tools were introduced within the Rotter-
dam region. In the period 1989-95, 4344 patients were
diagnosed with prostate cancer and the age-standardized
incidence increased from 62 to 125 per 100,000 men. This
increase mainly comprised of tumours localized to the
prostate, while the incidence of advanced cancers
remained stable. The proportion of poorly differentiated
tumours decreased from 33% in 1989 to 24% in 1995. In
the same period the number of patients receiving
radiotherapy increased from 80 to 258, while the annual
number of radical prostatectomies rose from 17 to 159
[39].
Screening in Germany
In Germany, men are entitled from aged 45 years to one
annual examination for early detection of cancerous
diseases and this examination is funded by the insurance
system. In the age group around 60 years about 15%
of the men participate and among 1,341,833 men
participating in 1987 a total of 1,638 new cases of prostate
cancer were detected. The survival rate of patients treated
by total prostatectomy is comparable to that of the
general population, when adjusted for age distribution
and it is possible that screening for prostate cancer might
reduce the mortality of the disease [40].
Screening in Austria
Horninger summarised the Austrian experience of
different prostate carcinoma screening projects: a PSA
cut-off of 2.5 ng/ml in men aged 45-49 years and of
3.5 ng/ml in men aged 50-59 years resulted in an 8%
increase in the detection rate of organ-confined disease
[41]. A total of 284/2272 (13%) had elevated PSA levels
and prostate carcinoma was detected in 62 of this group
(3%). All underwent radical prostatectomy and
histological examination revealed organ confined tumour
in all but eight. 98/340 (29%) had biopsies positive for
carcinoma; 28 of these patients (29%) had carcinoma
that originated in the transition zone only. In the second
prospective study, 120/465 (26%) with total PSA levels
between 1.25 ng/ml and 6.49 ng/ml and a percentage
FPSA<18% were further evaluated and 27 (23%) were
found to have prostate carcinoma. ROC curve analysis for
PSA transition zone density showed that by using a PSA
transition zone density of >22 ng/ml/cc as a biopsy
criterion, 24.4% of negative biopsies could be avoided
without missing a single carcinoma. High total PSA levels,
PSA density and PSA transition zone density correlated
significantly with high Gleason scores, capsular pene-
tration, a high percentage of cancer in the prostatectomy
specimen and a high cancer volume.
Screening in Sweden
A Swedish population based screening study was
undertaken in 1988-1989 [30]. 1782 men responded and
were examined with DRE, TRUS, and PSA testing
(Tandem-Hybritech). Of 1748 men a total of 367 under-
went TRUS guided biopsies because of abnormal findings
on either DRE or TRUS or serum PSA levels of greater
than 10 ng/ml. This resulted in the diagnosis of 64 cases of
prostate cancer (3.7%). PSA levels of ≥3.0 ng/ml were
found in 55 (86%) of 64 cancer cases and in 399 (24%) of
the 1684 benign cases. Among the 1294 with PSA
<3.0 ng/ml, nine prostate cancers were diagnosed. This
accounted for 14% of all prostate cancers. All 9/1294
with cancer and with PSA <3.0 ng/ml had a percentage
FPSA of ≤18%. In the group of 1109 with PSA
<3.0 ng/ml and a percentage FPSA >18%, 159 biopsies
were performed because of abnormal DRE or TRUS.
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However, no prostate cancer was diagnosed in this
category of patients. Five years after the screening
intervention, seven more cases of prostate cancer were
clinically diagnosed in the screened population according
to the Swedish Cancer Registry [30].
Screening in Finland
Approximately 20,000 men aged 55-67 years from two
areas in Finland were identified from the Finnish
Population Registry and randomised either to the
screening arm (1/3rd) or the control arm (2/3rd) of
a prostate cancer screening trial [31]. In the first round
of the study the participation rate in the screening
arm was 69%. Of the 5053 screened participants, 428
(8.5%) had a PSA concentration of ≥4.0 ng/ml and
diagnostic examinations were performed on 399. A total
of 106 cancers were detected among this group,
corresponding to a positive predictive value (PPV) of
27%. The prostate cancer detection rate based on a serum
PSA concentration of ≥4.0 ng/ml was 2.1%. Approxi-
mately 90% of screening detected prostate cancers were
localised, 85% were clinical stage T1-T2, and well or
moderately differentiated. A total of 42% were World
Health Organization grade I and 50% were grade II,
which suggests a higher proportion of curable cancers
compared with cases detected by other means [31].
Screening in Asia
Reports of prostate cancer screening are mainly from
Indonesia and Japan. PSA and PSAD values in Indonesia
have been found to be uniquely much higher than the
normally accepted values in Western countries [42]. The
most sensitive cut-off points to perform prostate biopsy
were a serum PSA level >8.0 ng/ml, and a PSAD of
>0.19 at an intermediate serum PSA level of 8-30 ng/ml
[17]. The ROC curve revealed an optimum cut-off level of
0.19. At this level of PSA density, the sensitivity of the
screening test was 100% and the specificity was 79%. The
study authors concluded that in their uncatheterized
patients (without retention) series, the PSAD cut-off level
for prostate biopsy of 0.19 was higher than that in the
Western world: 0.12 or 0.15 [42].
Since 1975 mass screening for prostate cancer has
been performed in Japan and the Prostate Research
Foundation has analysed the data every year that are
collected from all institutes performing a mass screening
[43]. Up to 1993, a total of 67, 225 subjects have been
examined and the detection rate of prostate cancer was
0.69%. Approximately half of the cancers were stage B
and those who had metastatic stage were only 20%. The
percentage of subjects with PSA levels of 0.05-4.0 ng/ml,
4.1-9.9 ng/ml and ≥10.0 ng/ml were respectively 89.6%,
7.0% and 3.4%. This distribution is approximately as the
same as previous reports from the United States and
Canada [43].
Ito reported on the mass screening for prostate
cancer in 9671 subjects during the period 1986-1998. The
initial screening method was measurement of prostatic
acid phosphatase during 1986-1991 and measurement of
PSA for the period 1992-1998. As a result, 303 cases of
prostate cancer were diagnosed. The prostate cancer
detection rate was 3.1% among all subjects observed
during the 13-year period. 62% of patients demonstrated
a PSA abnormality for more than one year, on average 2.8
years, before prostate cancer diagnosis. Prostate cancer
that was diagnosed within one year after a PSA value
became abnormal was not associated with bone
metastasis. Concerning the relationship between PSA
velocity (PSAV) and clinical stage, the proportion of stage
B cancers was 86% in the subjects whose PSAV level
before diagnosis was ≤0.18 ng/ml/year and it was only
29% in those with PSAV levels of ≥4.5 ng/ml/year. Only
3/86 (3.5%) with prostate cancer with PSAV levels of
≤4.4 ng/ml/year had bone metastasis, and two of these
three patients had poorly differentiated adenocarcinoma
[44].
Screening in Africa
Despite the absence of screening programs in Nigeria,
the number of prostate cancer cases has increased in the
Nigerian cancer registry, 1980-1996. Prostate cancer has
become the highest ranked cancer for incidence in
Nigerian men and constitutes 11% of all male cancers.
The median age of patients was 67.5 years and the mean
age was 71.4 years [45].
Conclusions
Prostate cancer is the most common cancer in men in
the Western world. The increasing prevalence of prostate
cancer can be attributed to a number of causes, including
relatively new detection modalities, the increasing life
span, and increased public awareness of the disease. The
increased awareness has resulted from information in the
lay press, recognition of prominent public figures who
are living with or have died from prostate cancer, and an
increasingly informed public. Currently one randomised
study from Quebec, Canada, has shown a survival benefit.
We eagerly await the results from the European and
American randomised studies. In addition, we also need
to find out the most effective method of screening in
order to minimise costs, unnecessary biopsies and the
anxiety of the general public.
Patricia Tai
Department of Radiation Oncology
Allan Blair Cancer Centre
4101 Dewdney Avenue
Regina
Saskatchewan S4T 7T1
Canada
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